^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986148

    i
    Other names: BMS-986148, BMS986148, BMS 986148
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    Tubulin inhibitor, Mesothelin-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    almost3years
    A Study of BMS-986148 in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=126, Terminated, Bristol-Myers Squibb | N=407 --> 126 | Active, not recruiting --> Terminated; Study terminated for business reasons not related to safety.
    Clinical • Enrollment change • Trial termination
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Opdivo (nivolumab) • BMS-986148
    3years
    Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. (PubMed, Clin Cancer Res)
    BMS-986148 {plus minus} nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.
    Clinical • P1/2 data • Journal • Combination therapy • PD(L)-1 Biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    Opdivo (nivolumab) • BMS-986148